Evidence map›Paper›PMID 39022099›Full record

ReviewHeliyon2024

Targeting sine oculis homeoprotein 1 (SIX1): A review of oncogenic roles and potential natural product therapeutics.

Zhiwei Bian, Menny M Benjamin, Lucas Bialousow, Yintai Tian, G Aaron Hobbs, Dev Karan, Yeun-Mun Choo, Mark T Hamann, Xiaojuan Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhiwei BianSchool of Pharmacy, Lanzhou University, Lanzhou, 730000, Gansu, China.
Menny M BenjaminDrug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA.
Lucas BialousowDrug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA.
Yintai TianSchool of Pharmacy, Lanzhou University, Lanzhou, 730000, Gansu, China.
G Aaron HobbsHollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Dev KaranDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.
Yeun-Mun ChooChemistry Department, Faculty of Science, University of Malaya, 50603, Kuala Lumpur, Malaysia.
Mark T HamannDrug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA.
Xiaojuan WangSchool of Pharmacy, Lanzhou University, Lanzhou, 730000, Gansu, China.

Funding

Synthesis and Optimization of the Aleutianamine Class of AlkaloidsR01GM145845 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HAMANN, MARK T, TIUS, MARCUS ANTONIUS · 2022 to 2025
$2.4M
NIGMS NIH HHS R01 GM145845
6 · The paper itself

Abstract

Sine oculis homeoprotein 1 (SIX1), a prominent representative of the homeodomain transcription factors within the SIX family, has attracted significant interest owing to its role in tumorigenesis, cancer progression, and prognostic assessments. Initially recognized for its pivotal role in embryonic development, SIX1 has emerged as a resurgent factor across a diverse set of mammalian cancers. Over the past two decades, numerous investigations have emphasized SIX1's dual significance as a developmental regulator and central player in oncogenic processes. A mounting body of evidence links SIX1 to the initiation of diverse cancers, encompassing enhanced cellular metabolism and advancement. This review provides an overview of the multifaceted roles of SIX1 in both normal development and oncogenic processes, emphasizing its importance as a possible therapeutic target and prognostic marker. Additionally, this review discusses the natural product agents that inhibit various pro-oncogenic mechanisms associated with SIX1.

Indexed as

And metabolismMetastasisNatural productsSine oculis homeoprotein 1 (SIX1)

Identifiers

PMID39022099
PMCPMC11252760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.